Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Botezatu, Ancaa | Iancu, Iulia V.a; * | Plesa, Adrianaa | Manda, Danab | Popa, Oanab | Bostan, Marinelaa | Mihaila, Mirelaa | Albulescu, Adriana; c | Fudulu, Alinaa | Vladoiu, Susana V.b | Huica, Irinaa | Dobrescu, Ruxandrab; d | Anton, Gabrielaa | Badiu, Corinb; d
Affiliations: [a] ‘Stefan S. Nicolau’ Institute of Virology, Bucharest, Romania | [b] ‘CI Parhon’ National Institute of Endocrinology, Bucharest, Romania | [c] National Institute for Chemical pharmaceutical Research and Development, Calea Vitan, Romania | [d] ‘Carol Davila’ University of Medicine and Pharmacy, Bucharest, Romania
Correspondence: [*] Corresponding author: Iulia V. Iancu, %****␣cbm-25-cbm182265_temp.tex␣Line␣25␣**** ‘Stefan S. Nicolau’ Institute of Virology, 285 Mihai Bravu Ave, Bucharest 030304, Romania. Tel./Fax: +40 21 324 25 90; E-mail: iulia_iancu2005@yahoo.com.
Abstract: BACKGROUND: Thyroid carcinoma is the most common endocrine malignancy worldwide. Changes in DNA methylation can cause silencing of normally active genes, especially tumour suppressor genes (TSG) or activation of normally silent genes. OBJECTIVE: The aim of this study is to evaluate the degree of promoter methylation for a panel of markers for thyroid neoplasms and to establish their relationship with thyroid oncogenesis. METHODS: To generate a comprehensive DNA methylation signature of TSGs involved in thyroid neoplasia, we use Human TSG EpiTect Methyl II Signature PCR Array-Qiagen for 24 samples (follicular adenomas and papillary thyroid carcinomas) compared with normal thyroid tissue. We extended the evaluation for three TSGs (TP73, WIF1, PDLIM4) using qMS-PCR. Statistical analysis was performed with GraphPad Prism. RESULTS: We noted four important genes NEUROG1, ESR1, RUNX3, MLH1, which presented methylated promoter in tumour samples compared to normal. We found new characteristic of thyroid tumours: methylation of TP73, WIF1 and PDLIM4 TSGs, which can contribute to thyroid neoplasia. A significant correlation between BRAF V600E mutation and RET/PTC rearrangements with TIMP3 and CDH13, RARB methylation, respectively was observed. CONCLUSIONS: TSGs promoter hypermethylation is a hallmark of cancer and a test that uses methylation quantification method is suitable for diagnosis and prognosis of thyroid cancer.
Keywords: Thyroid cancer, tumour suppressor genes, promoter methylation, epigenetics
DOI: 10.3233/CBM-182265
Journal: Cancer Biomarkers, vol. 25, no. 1, pp. 53-65, 2019
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl